MedTrace Logo

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

NCT04165564 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2026-04-01

No results posted yet for this study

Summary

DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately, this study aims to validate molecular as well as clinical and imaging biomarkers of lung cancer in individuals with indeterminate lung nodules.

Conditions

  • Pulmonary Disease

Interventions

OTHER

Institutional standard of care

Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)

OTHER

Biosamples of airway and blood

Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.

Sponsors & Collaborators

  • Johnson & Johnson

    collaborator INDUSTRY

  • American College of Radiology Imaging Network

    collaborator NETWORK

  • Boston University

    lead OTHER

Principal Investigators

  • Ehab Billatos, MD · Boston University

  • Denise Aberle, MD · University of California, Los Angeles

  • George Washko, MD · Brigham and Women's Hospital

Eligibility

Min Age
46 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-24
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04165564 on ClinicalTrials.gov